{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:58Z","timestamp":1786119358389,"version":"build-2736575974"},"reference-count":113,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>mRNA vaccines consist of antigen-encoding mRNA, which produces the antigenic protein upon translation. Coupling antigen production with innate immune activation can generate a potent, antigen-specific T-cell response. Clinical reports have demonstrated the ability of mRNA vaccines to elicit an anticancer immune response against various tumor types. Here, we discuss strategies to enhance the potency of mRNA vaccines. We provide an overview of existing knowledge regarding the activation and trafficking mechanisms of mRNA vaccines and share optimization strategies to boost mRNA-mediated antigen production. In addition, we address methods to target mRNA vaccines to dendritic cells and lymph nodes, key initiators of the immune response. Finally, we review strategies for enhancing immune activation using adjuvants compatible with mRNA vaccines. mRNA vaccines offer unique advantages that can be utilized for oncology applications. However, significant work is needed to understand their underlying mechanisms and develop technologies to improve their effectiveness.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000764","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:26:00Z","timestamp":1742847960000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Improving the Efficacy of Cancer mRNA Vaccines"],"prefix":"10.1097","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3779-0363","authenticated-orcid":false,"given":"Ameya R.","family":"Kirtane","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Traverso","sequence":"additional","affiliation":[{"name":"Department of Mechanical Engineering, Massachusetts Institute of Technology"},{"name":"Broad Institute, Massachusetts Institute of Technology, Cambridge, MA"},{"name":"Department of Gastroenterology, Hepatology and Endoscopy, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3]]},"reference":[{"key":"R1-20250324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"R2-20250324","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/jca.5046","article-title":"Dendritic cells in the cancer microenvironment","volume":"4","author":"Ma","year":"2012","journal-title":"J Cancer"},{"key":"R3-20250324","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Tran Janco","year":"2015","journal-title":"J Immunol"},{"key":"R4-20250324","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the knowledge of sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann Surg"},{"key":"R5-20250324","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2010.29.7499","article-title":"Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen\u2014A24 with recurrent or progressive glioblastoma multiforme","volume":"29","author":"Terasaki","year":"2011","journal-title":"J Clin Oncol"},{"key":"R6-20250324","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R7-20250324","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.21037\/tlcr-21-1","article-title":"Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R8-20250324","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/01.cji.0000171291.72039.e2","article-title":"Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial","volume":"28","author":"Lee","year":"2005","journal-title":"J Immunother"},{"key":"R9-20250324","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"R10-20250324","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"R11-20250324","doi-asserted-by":"crossref","first-page":"887125","DOI":"10.3389\/fimmu.2022.887125","article-title":"mRNA Vaccines: the dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol [Internet]"},{"key":"R12-20250324","first-page":"1","article-title":"mRNA Vaccines in Cancer Treatment","volume":"1","author":"Zhou","year":"2023","journal-title":"MedScien"},{"key":"R13-20250324","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R14-20250324","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","article-title":"Influence of protein fold stability on immunogenicity and its implications for vaccine design","volume":"16","author":"Scheiblhofer","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"R15-20250324","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1172\/JCI16428","article-title":"Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting","volume":"110","author":"Dutoit","year":"2002","journal-title":"J Clin Invest"},{"key":"R16-20250324","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"R17-20250324","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R18-20250324","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"R19-20250324","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"R20-20250324","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"R21-20250324","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2024.01.037","article-title":"Quality assessment of LNP-RNA therapeutics with orthogonal analytical techniques","volume":"367","author":"Parot","year":"2024","journal-title":"J Controlled Release"},{"key":"R22-20250324","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"R23-20250324","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J Pharm Sci"},{"key":"R24-20250324","doi-asserted-by":"crossref","first-page":"1246682","DOI":"10.3389\/fimmu.2023.1246682","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol [Internet]"},{"key":"R25-20250324","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.matt.2021.12.022","article-title":"Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections","volume":"5","author":"Abramson","year":"2022","journal-title":"Matter"},{"key":"R26-20250324","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12248-023-00844-z","article-title":"Gastrointestinal delivery of an mRNA vaccine using immunostimulatory polymeric nanoparticles","volume":"25","author":"Kim","year":"2023","journal-title":"AAPS J"},{"key":"R27-20250324","doi-asserted-by":"crossref","first-page":"e2301606120","DOI":"10.1073\/pnas.2301606120","article-title":"Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination","volume":"120","author":"Ben-Akiva","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"R28-20250324","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J Controlled Release"},{"key":"R29-20250324","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2024.03.022","article-title":"Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity","volume":"32","author":"Abbasi","year":"2024","journal-title":"Mol Ther"},{"key":"R30-20250324","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"R31-20250324","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","article-title":"Visualization of early events in mRNA vaccine delivery in non-human primates via PET\u2013CT and near-infrared imaging","volume":"3","author":"Lindsay","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"R32-20250324","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jconrel.2020.11.033","article-title":"Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants","volume":"330","author":"Blakney","year":"2021","journal-title":"J Controlled Release"},{"key":"R33-20250324","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"R34-20250324","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"R35-20250324","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"R36-20250324","doi-asserted-by":"crossref","first-page":"e1010255","DOI":"10.1371\/journal.ppat.1010255","article-title":"Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses","volume":"18","author":"Ndeupen","year":"2022","journal-title":"PLOS Pathog"},{"key":"R37-20250324","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","article-title":"The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system","volume":"32","author":"Bernard","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"R38-20250324","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"R39-20250324","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"R40-20250324","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat Commun"},{"key":"R41-20250324","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","article-title":"Human 5\u2032 UTR design and variant effect prediction from a massively parallel translation assay","volume":"37","author":"Sample","year":"2019","journal-title":"Nat Biotechnol"},{"key":"R42-20250324","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: the art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"R43-20250324","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"R44-20250324","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molcel.2017.11.014","article-title":"A massively parallel reporter assay of 3\u2032 UTR sequences identifies in vivo rules for mRNA degradation","volume":"68","author":"Rabani","year":"2017","journal-title":"Mol Cell"},{"key":"R45-20250324","doi-asserted-by":"crossref","first-page":"jkab404","DOI":"10.1093\/g3journal\/jkab404","article-title":"Massively parallel analysis of human 3\u2032 UTRs reveals that AU-rich element length and registration predict mRNA destabilization","volume":"12","author":"Siegel","year":"2022","journal-title":"G3 (Bethesda)"},{"key":"R46-20250324","first-page":"1","article-title":"Branched chemically modified poly(A) tails enhance the translation capacity of mRNA","volume":"43","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"R47-20250324","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"R48-20250324","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"R49-20250324","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"R50-20250324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol Ther - Nucleic Acids"},{"key":"R51-20250324","doi-asserted-by":"crossref","first-page":"e2309472120","DOI":"10.1073\/pnas.2309472120","article-title":"Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects","volume":"120","author":"Chen","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"R52-20250324","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat Biotechnol"},{"key":"R53-20250324","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.nanolett.9b03483","article-title":"Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination","volume":"20","author":"Son","year":"2020","journal-title":"Nano Lett"},{"key":"R54-20250324","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR\u2013Cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat Mater"},{"key":"R55-20250324","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"R56-20250324","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"R57-20250324","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.1021\/acsnano.4c01171","article-title":"High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route","volume":"18","author":"Hamilton","year":"2024","journal-title":"ACS Nano"},{"key":"R58-20250324","doi-asserted-by":"crossref","first-page":"e2207841119","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node\u2013targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"R59-20250324","doi-asserted-by":"crossref","first-page":"30701","DOI":"10.1021\/acsnano.4c09902","article-title":"Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo","volume":"18","author":"Luo","year":"2024","journal-title":"ACS Nano"},{"key":"R61-20250324","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.imbio.2008.11.004","article-title":"Influence of the mannose receptor in host immune responses","volume":"214","author":"Gazi","year":"2009","journal-title":"Immunobiology"},{"key":"R62-20250324","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3389\/fphar.2018.00980","article-title":"Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol [Internet]"},{"key":"R63-20250324","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2018.03.035","article-title":"Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells","volume":"278","author":"Le Moignic","year":"2018","journal-title":"J Controlled Release"},{"key":"R64-20250324","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.mtbio.2024.101136","article-title":"Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1\/PD-L1 blockade","volume":"27","author":"Jin","year":"2024","journal-title":"Mater Today Bio"},{"key":"R65-20250324","doi-asserted-by":"crossref","first-page":"e202318515","DOI":"10.1002\/anie.202318515","article-title":"Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability","volume":"63","author":"Lei","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"R66-20250324","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/imm.13777","article-title":"Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen","volume":"172","author":"Li","year":"2024","journal-title":"Immunology"},{"key":"R67-20250324","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat Rev Mater"},{"key":"R68-20250324","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41565-020-0679-4","article-title":"Programmable multistage drug delivery to lymph nodes","volume":"15","author":"Schudel","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"R69-20250324","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owensiii","year":"2006","journal-title":"Int J Pharm"},{"key":"R70-20250324","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jconrel.2024.08.018","article-title":"Stealth mRNA nanovaccines to control lymph node trafficking","volume":"374","author":"Garc\u00eda-Fern\u00e1ndez","year":"2024","journal-title":"J Controlled Release"},{"key":"R71-20250324","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/pharmaceutics16040455","article-title":"Immune specific and tumor-dependent mRNA vaccines for cancer immunotherapy: reprogramming clinical translation into tumor editing therapy","volume":"16","author":"Katopodi","year":"2024","journal-title":"Pharmaceutics"},{"key":"R72-20250324","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J Immunol"},{"key":"R73-20250324","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","article-title":"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells","volume":"162","author":"Curtsinger","year":"1999","journal-title":"J Immunol"},{"key":"R74-20250324","first-page":"1","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"Part 1","key":"R75-20250324","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"L\u00f3pez de Padilla","year":"2016","journal-title":"Gene"},{"key":"R76-20250324","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol Ther"},{"key":"R77-20250324","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"R78-20250324","doi-asserted-by":"crossref","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"Ramos da Silva","year":"2023","journal-title":"Sci Transl Med"},{"key":"R79-20250324","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"R80-20250324","doi-asserted-by":"crossref","first-page":"e2214320120","DOI":"10.1073\/pnas.2214320120","article-title":"Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment","volume":"120","author":"Tockary","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"R81-20250324","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","article-title":"mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response","volume":"29","author":"Tse","year":"2021","journal-title":"Mol Ther"},{"key":"R82-20250324","doi-asserted-by":"crossref","first-page":"e0250623","DOI":"10.1128\/mbio.02506-23","article-title":"mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines","volume":"14","author":"Zhivaki","year":"2023","journal-title":"mBio"},{"key":"R83-20250324","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R84-20250324","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R85-20250324","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat Biotechnol"},{"key":"R86-20250324","first-page":"1","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","author":"Li","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"R87-20250324","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ymthe.2024.01.020","article-title":"Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines","volume":"32","author":"Kubara","year":"2024","journal-title":"Mol Ther"},{"key":"R88-20250324","doi-asserted-by":"crossref","first-page":"19218","DOI":"10.1021\/jacs.4c04331","article-title":"Stimuli-responsive mRNA vaccines to induce robust CD8+ T cell response via ROS-mediated innate immunity boosting","volume":"146","author":"Dong","year":"2024","journal-title":"J Am Chem Soc"},{"key":"R89-20250324","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0009-2797(93)90117-H","article-title":"Biological and toxicological consequences of quinone methide formation","volume":"86","author":"Thompson","year":"1993","journal-title":"Chem Biol Interact"},{"key":"R90-20250324","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1093\/nar\/gkx306","article-title":"The non-stop decay mRNA surveillance pathway is required for oxidative stress tolerance","volume":"45","author":"Jamar","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"R91-20250324","doi-asserted-by":"crossref","first-page":"32689","DOI":"10.1021\/jacs.4c12166","article-title":"Manganese oxide-incorporated hybrid lipid nanoparticles amplify the potency of mRNA vaccine via oxygen generation and STING activation","volume":"146","author":"Gan","year":"2024","journal-title":"J Am Chem Soc"},{"key":"R92-20250324","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1189\/jlb.0108023","article-title":"Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention","volume":"84","author":"Wu","year":"2008","journal-title":"J Leukoc Biol"},{"key":"R93-20250324","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"R94-20250324","doi-asserted-by":"crossref","first-page":"18758","DOI":"10.1021\/acsnano.3c02251","article-title":"An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses","volume":"17","author":"Oyama","year":"2023","journal-title":"ACS Nano"},{"key":"R95-20250324","doi-asserted-by":"crossref","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"R96-20250324","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jconrel.2024.07.051","article-title":"Engineering CaP-pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations","volume":"373","author":"Wu","year":"2024","journal-title":"J Controlled Release"},{"key":"R97-20250324","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"R98-20250324","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1172\/JCI74337","article-title":"Cytokine therapy reverses NK cell anergy in MHC-deficient tumors","volume":"124","author":"Ardolino","year":"2014","journal-title":"J Clin Invest"},{"key":"R99-20250324","doi-asserted-by":"crossref","first-page":"C1205","DOI":"10.1152\/ajpcell.00039.2011","article-title":"Ca2+ signaling in the regulation of dendritic cell functions","volume":"300","author":"Shumilina","year":"2011","journal-title":"Am J Physiol-Cell Physiol"},{"key":"R100-20250324","doi-asserted-by":"crossref","first-page":"693709","DOI":"10.3389\/fimmu.2021.693709","article-title":"The use of iron oxide nanoparticles to reprogram macrophage responses and the immunological tumor microenvironment","volume":"12","author":"Mulens-Arias","year":"2021","journal-title":"Front Immunol"},{"key":"R101-20250324","doi-asserted-by":"crossref","first-page":"2301261","DOI":"10.1002\/adhm.202301261","article-title":"Hybrid mRNA nano vaccine potentiates antigenic peptide presentation and dendritic cell maturation for effective cancer vaccine therapy and enhances response to immune checkpoint blockade","volume":"12","author":"Shi","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"R102-20250324","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biomaterials.2018.12.019","article-title":"Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation","volume":"195","author":"Coolen","year":"2019","journal-title":"Biomaterials"},{"key":"R103-20250324","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2020.08.023","article-title":"DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine","volume":"328","author":"Zhang","year":"2020","journal-title":"J Controlled Release"},{"key":"R104-20250324","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1021\/acsnano.3c11637","article-title":"Self-adjuvanting polyguanidine nanovaccines for cancer immunotherapy","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"key":"R105-20250324","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41551-023-01131-0","article-title":"Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity","volume":"8","author":"Zhu","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"R106-20250324","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J Controlled Release"},{"key":"R107-20250324","first-page":"1655","article-title":"Broadening the message: a nanovaccine co-loaded with messenger RNA and \u03b1-GalCer induces antitumor immunity through conventional and natural killer T cells","volume":"13","author":"Verbeke","year":"2019","journal-title":"ACS Nano"},{"key":"R108-20250324","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2024.04.052","article-title":"Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria","volume":"370","author":"Meulewaeter","year":"2024","journal-title":"J Controlled Release"},{"key":"R109-20250324","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.2147\/IJN.S479741","article-title":"Nasal mRNA nanovaccine with key activators of dendritic and MAIT cells for effective against lung tumor metastasis in mice model","volume":"19","author":"Li","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"R110-20250324","doi-asserted-by":"crossref","first-page":"2109984","DOI":"10.1002\/adma.202109984","article-title":"Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine","volume":"34","author":"Li","year":"2022","journal-title":"Adv Mater"},{"key":"R111-20250324","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1021\/acsabm.4c01239","article-title":"A self-amplifying human papillomavirus 16 vaccine candidate delivered by tobacco mosaic virus-like particles","volume":"7","author":"Karan","year":"2024","journal-title":"ACS Appl Bio Mater"},{"key":"R112-20250324","doi-asserted-by":"crossref","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"R113-20250324","doi-asserted-by":"crossref","first-page":"2311574","DOI":"10.1002\/adma.202311574","article-title":"Supramolecular lipid nanoparticles based on host\u2013guest recognition: a new generation delivery system of mRNA vaccines for cancer immunotherapy","volume":"36","author":"Qi","year":"2024","journal-title":"Adv Mater"},{"key":"R114-20250324","first-page":"1","article-title":"Incorporation of a Toll-like receptor 2\/6 agonist potentiates mRNA vaccines against cancer and infectious diseases","volume":"8","author":"Gu","year":"2023","journal-title":"Signal Transduct Target Ther"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:21:40Z","timestamp":1786040500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000764","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2025-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}